Preclinical studies have suggested that the anti-tumor activity of CSF-1R blockade can be counteracted by chemokines-mediated recruitment of polymorphonuclear MDSCs, diminishing the overall efficacy [221]. The gene discussed is CSF1R; the disease is neoplasm.